Ann: Receipt of R&D Tax Incentive, page-14

Kens may have a point though BD. Even with a consolidation and CR - there have to be investors willing to have confidence in the company. The legal cost burden - which may not be as big as we all fear -  is likely to dampen enthusiasm.

Does POH have enough products and IP to warrant it being a feasible investment opportunity? Can it ever realise any of that potential if the legal costs are indeed substantial? Can it even recover from what is a very serious body blow. Essentially, POH finds itself in a worse situation than it was in after the Esra betrayal. It had around $14 in cash back then and no legal cost burden hanging over its head. Plus it was to recover over $3mil from the stolen cash.

I have a real soft spot for POH - it was the first share I invested in 2011/12. Been saddened by its decline not to mention losing $35k. Having said that, we could be looking at a company staring insolvency in the face. Can't say I have the expertise to judge the true value of its products and science but there may be a lot of hope over logic being played out here.

If the threat of legal cost sanctions are to remain for any lengthy time, that will also bear down on investor sentiment. At the moment (and a surprise to me) there are around 300mil shares being sought. 250mil of those are at the discounted price of .02 and .01 cents and I suspect this represents the "could be a nice gamble" component of the market. Buy in at this price with the thought that situation could provide a saviour could result in the SP rising a bit - maybe with a take-over. I suspect anyway that bids this low do not represent real investor confidence in the company.

BD - do you see anything from Terumo to suggest they may influence the outcome? Would they be willing to absorb POH?

Kens animal health has been ticking away for some time now,Ross has always been enthusiastic about it and due to the already elapsed time maybe that could be another near term get out of jail card.